Zydus Cadila seeks DCGI nod for emergency use of its Covid-19 vaccine ZyCoV-D
The Phase 3 trials on more than 28,000 volunteers across 50 clinical sites, have shown an efficacy rate of 66.6%. That is lower than the efficacy levels of vaccines from Moderna and Pfizer-BioNTech that use mRNA technology. Zydus Cadila, which has sought the approval of DCGI for emergency use authorisation of its vaccine ZyCoV-D following … Read more